首頁 - Lee's Pharmaceutical Taiwan | 李氏大藥廠

Corporate Spirit
Science, our belief and aspiration
Mission
Commit to R&D of innovative products to address unmet medical needs and to improve patients’ quality of life.

Corporate Spirit
Science, our belief and aspiration
Mission
Commit to R&D of innovative products to address unmet medical needs and to improve patients’ quality of life.

Concentrated medical researcher using digital tablet

LEE’S PHARMACEUTICAL HOLDINGS LIMITED

關於李氏大藥廠

李氏大藥廠創立於 1994 年,自成立以來,便致力於自行研發與生產專科藥物,並將主要市場定位於亞太市場。專注於心臟、婦科、眼科、腫瘤及皮膚科等專科領域,李氏大藥廠憑藉其強大的科研實力,已成功研製並註冊了五種專科藥物,逐步奠定了其在行業內的領導地位。

更多關於李氏

熱門商品推薦HOT SALES

LATEST NEWS

最新消息

Azilsartan Tablets won the “Guangdong Prominent High-tech Products” award

Recently, the Guangdong High-tech Association granted the certificates of “Guangdong Prominent High-tech Products” for 2023...

The Group featured in “Top100 Chinese Chemical Pharmaceutical Companies Ranking”, with its product winning award again

The 2024 China Medical and Health Industry Symbiosis Conference, organized by Menet, a healthcare information platform, was grandly held in Huzhou...

The Group’s in-house developed product Adapalene and Clindamycin Hydrochloride Gel was successfully launched

May 30, 2024, Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) grandly held the launch ceremony at...

The Group’s in-licensed products INOmax® and INOmax DSIR Plus were successfully launched

Recently, the "Symposium on the Progress of Nitric Oxide Inhalation Therapy in Newborns" organized by the Shanghai Caritas Foundation...

Azilsartan Tablets won the “Guangdong Prominent High-tech Products” award

Recently, the Guangdong High-tech Association granted the certificates of “Guangdong Prominent High-tech Products” for 2023...

The Group featured in “Top100 Chinese Chemical Pharmaceutical Companies Ranking”, with its product winning award again

The 2024 China Medical and Health Industry Symbiosis Conference, organized by Menet, a healthcare information platform, was grandly held in Huzhou...

The Group’s in-house developed product Adapalene and Clindamycin Hydrochloride Gel was successfully launched

May 30, 2024, Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) grandly held the launch ceremony at...

The Group’s in-licensed products INOmax® and INOmax DSIR Plus were successfully launched

Recently, the "Symposium on the Progress of Nitric Oxide Inhalation Therapy in Newborns" organized by the Shanghai Caritas Foundation...

Azilsartan Tablets won the “Guangdong Prominent High-tech Products” award

Recently, the Guangdong High-tech Association granted the certificates of “Guangdong Prominent High-tech Products” for 2023...

The Group featured in “Top100 Chinese Chemical Pharmaceutical Companies Ranking”, with its product winning award again

The 2024 China Medical and Health Industry Symbiosis Conference, organized by Menet, a healthcare information platform, was grandly held in Huzhou...

The Group’s in-house developed product Adapalene and Clindamycin Hydrochloride Gel was successfully launched

May 30, 2024, Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) grandly held the launch ceremony at...

The Group’s in-licensed products INOmax® and INOmax DSIR Plus were successfully launched

Recently, the "Symposium on the Progress of Nitric Oxide Inhalation Therapy in Newborns" organized by the Shanghai Caritas Foundation...

RESEARCH & DEVELOPMENT

研究與開發

主要治療領域

主要治療領域聚焦於疾病管理、功能恢復、預防健康促進及心理支持，透過多領域協作提升患者生活品質與健康成果

產品研發

coming soon

PARTNERS

合作夥伴

CONTACT US

聯絡我們

LEE’S PHARMACEUTICAL HOLDINGS LIMITED

聯絡方式

info@leespharm.com.tw
+886 2 2758 3090
+886 2 2758 3005
11073 台北市信義區松仁路36號11樓

網站地圖